Nkarta NKTX 深 沪
等待开盘 08-01 09:30:00 美东时间
2.17
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.17
- 总市值 1.54亿
- 52周最高 6.6279
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.31
- 委 比 0.00%
- 总股本 7095.76万
- 历史最高 79.16
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.28
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered NK cell therapies, will participate in the H.C. Wainwright "HCW@Home" Series. The event will feature a fireside chat on July 30, 2025, at 11:00 a.m. ET, and registration is available via the provided link. Nkarta is advancing allogeneic NK cell therapies for autoimmune diseases using cell engineering and genome-editing technologies. The company aims to develop accessib...
07-23 12:01
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $14
Mizuho analyst Salim Syed maintains Nkarta (NASDAQ:NKTX) with a Outperform and lowers the price target from $16 to $14.
06-10 22:14
Nkarta Announces Leadership Change with New CMO
Nkarta ( ($NKTX) ) just unveiled an update. On June 3, 2025, Nkarta announced t...
06-06 21:48
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position.
05-16 03:46
Needham Maintains Buy on Nkarta, Lowers Price Target to $10
Needham analyst Gil Blum maintains Nkarta (NASDAQ:NKTX) with a Buy and lowers the price target from $11 to $10.
05-15 19:25
William Blair Downgrades Nkarta to Market Perform
William Blair analyst Sami Corwin downgrades Nkarta (NASDAQ:NKTX) from Outperform to Market Perform.
05-15 19:23
FDA staff cuts are already impacting regulatory work, Biotech leaders warn
A group of biotech CEOs, investors, and patient advocates have urged Senate HELP Committee Chairman Bill Cassidy (R-LA) to intervene amid an ongoing restructuring program at the FDA which they said ha...
04-10 23:37
